drugset

drugset / Trial / NCT06099613

Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult

NCT06099613 ↗

Phase 1/2 Completed 40 enrolled EyeGene Inc.

NaSequentialOpen-labelPrevention

Summary

This is a Phase I/IIa Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVII in Healthy Adult Volunteers

Timeline

Start: 2023-11-30
Primary completion: 2024-11-01
Completion: 2025-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EG-COVII	Vaccine	—	—

Indications